Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month,

Pfizer Ltd. share price jumped over 6% in Thursday's session as the company reported an increase in its net profit during July–September. Pfizer's bottom line increased 19.4% on the year to Rs 189 crore compared to Rs 158 crore in the same period of the previous financial year.

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend stability. Click here to read.

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an amended acquisition proposal to Metsera for $62.20 per share, a total value of $7.2 billion. Shortly after receiving the amended proposal, Metsera’s board of directors suggested to stockholders to approved Pfizer’s acquisition. 3

Danish company vies with US drugmaker for control of Metsera as they seek edge in growing market for weight-loss drugs

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million in value and announced this year. M&A, however, has not been enough for what the Goldman analysts say will be a third year of underperformance vs.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what I see in store for PFE and MTSR stock.

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo Nordisk ( NVO +0.47%) and Eli Lilly ( LLY +4.57%) slugging it out, while Pfizer ( PFE 0.16%) is looking to enter the fray.